


INTRODUCTION

Methods for the analysis of networks allow identifying groups of tightly connected genes whose activity may be altered during disease progression or due to chemical agents. Connectivity-based comparisons help identify “aggregate changes” that could be missed by standard methods of differential analysis comparing individual genes. In this work we compared networks obtained from wild type liver samples and from samples collected after the exposure to chemicals with varying carcinogenicity and genotoxicity.



METHODS


Two large cohorts of organ-specific **gene expression** profiles from controls and from rats exposed to chemical compounds



11244 expression profiles
376 chemicals
Liver, kidney, heart, muscle, hepatocytes




11244 expression profiles
131 chemicals
Liver, kidney, hepatocytes



Network and modules inference

Pearson Correlation between gene expression profiles

Dynamic tree cutting clustering



b) SFN

a) CN

Scale free transformations


Threshold on correlation to fit a “scale free” topology

Gene similarity matrix

REFERENCES

[1] Zhang B et al. (2013). Cell 153(3):707-20; [2] Schadt EE et al. (2009). Nat Rev Drug Discov 8: 286–295; [3] Gusenleitner D. et al. (2014). PLoS One. 24;9(7):e102579; [4] Zhang, B. et al. (2005). Stat. Appl. Genet. Mol. Biol. 4, e17.

Module differential connectivity



Validation

Systematic comparison of networks from the same tissue and conditions (liver control). Expected:

- Similar modules composition
- No differential connectivity → MDC = 1

TG-GATES


Scale free transformations

	Yes (SFN)	No (CN)
Avg. MDCs = 1	✓	✓
MDC variance	0.002286	0.000214
Not threshold-dependent	✗	✓

1. Compounds-specific network inference


DrugMatrix Samples from compound “C1”

CN



Repeat for C1, ..., C62 with at least 10 samples

2. Grouping of similar compounds



Repeat for all pairs of compounds

3. Differential analysis

Control samples DrugMatrix

CN

Healthy

M2

M3

M1

MDC


Compound group G1

M1 M2 Mn

healthy modules

Repeat for compound groups G1, ..., Gm

connectivity
LOSS GAIN





Biological function of gene modules (Enrichment)

RESULTS

2. Grouping of similar compounds

- Good separation of genotoxic and carcinogen compounds based on the similarity of their network structure
- 13 groups of compounds identified (Dynamic Tree Cutting)



- Mostly homogeneous groups in terms of DrugBank actions
- Significance of overlap of drug-interacting proteins within each group (CTD interaction database, p-values: Fisher exact test).

G1: 4.6e-11*, G2: 7.7e-11*, G3: 6.1e-12*, G4: NA, G5: 3.6e-11*, G6: 5.1e-11*, G7: 5e-4, G8: 0.04, G9: 0.002, G10: 1e-6, G11: 0.001, G12: 3.9e-11*, G13: 0.01

* = lower p-value cannot be obtained by chance (permutations)

3. Differential analysis

- 6315 genes, 60 “healthy” gene modules
- Identification of top 3 modules specifically altered by each compounds group (scoring) → GO/KEGG Enrichment

GROUP	MAIN ACTION	FUNCTIONS OF SPECIFICALLY ALTERED GENE MODULES
G1	SOLVENTS	Response to chemical stimulus, signaling
G2	ANTIFUNGALS	Response to chemical stimulus, development
G3	STATINS	Steroid biosynthesis, lipid metabolism
G4	ESTROGENS	DNA replication, development
G5	FIBRATES	Fatty acid metabolism
G6	n.c. (estrogen, antifung.)	mRNA processing, proliferation
G7	STERIODS	Development, transcription
G8	ANTI-CANCER	Cell development, apoptosis, signaling
G9	CHEMOTHERAPEUTICS	Cell. organization, DNA damage response
G10	ALKILATING- CANCER	Reg. of transcription, cancer pathways
G11	n.c. (anti-cancer, estrog)	DNA replication, response to stimulus
G12	ANTI-INFLAMM/ FUNGAL	Chemotaxis, immune response, development
G13	ANTISEPTICS / ESTROGENS	Development, DNA replication

Pathways actually related to the chemicals’ action. Examples of altered connectivity:

- GOC of lipid metabolism modules when Statins or Fibrates are used to reduce cholesterol;
- LOC of cell cycle modules in response to Chemotherapeutics